Search Results
Beyond Blankets: Subaru Loves to Care brings comfort and warmth
Blood cancer treatment can be a scary and confusing time. And blood cancer patients want to feel like they’re not alone.
That’s why The Leukemia & Lymphoma Society (LLS) and Subaru are partnering to bring warmth and comfort to blood cancer patients through warm blankets, patient care kits, and handwritten notes of encouragement.
Targeting AML
Not for lack of trying, we’ve seen very little progress over the past 40 years in treating acute myeloid leukemia (AML), an aggressive and deadly blood cancer. But we’re finally starting to see the needle move and The Leukemia & Lymphoma Society (LLS) is playing a leading role in going on the offensive against the disease.
Statement on the Death of Supreme Court Justice and Trailblazer Ruth Bader Ginsburg
Photo by Nikki Khan/The Washington Post via Getty Images
Here at The Leukemia & Lymphoma Society (LLS), we are devastated to learn of the passing of Associate Justice Ruth Bader Ginsburg from complications of metastatic pancreatic cancer. As the global leader in the fight against blood cancer, we stand with the cancer community – and all Americans – in mourning this trailblazer whose contributions to public health and equality will be felt by generations to come.
Meet an LLS Advocacy Volunteer: Amanda Steffy
Amanda Steffy of Pasadena, Calif. is one of The Leukemia & Lymphoma Society’s most passionate policy advocates. She frequently travels to Washington, D.C. to speak with lawmakers about the importance of high-quality, affordable healthcare for cancer patients. In California, where she works as an instrument systems engineer for NASA JPL, she recruits and teaches others to do the same.
This May, Steffy joins LLS for its first-ever virtual advocacy event. In this interview, Steffy explains how she first became involved in advocacy and why she’s so passionate about the work.
Leveraging cancer registries, clinical trials, and community partnerships to address disparities in pediatric, adolescent, and young adult lymphoma
I aim to identify drivers of pediatric and adolescent/young adult lymphoma disparities so that targeted health equity interventions can be developed. Integration of large datasets, systematic collection of social determinants data in clinical trials, and collaboration with patient advocates will: a) create new population-based resources to study lymphoma outcomes; b) establish a novel framework for equity research in lymphoma clinical trials; and c) identify real-world targets for intervention.Burlington Launches Point of Sale Campaign to Benefit LLS September - December
"A Style for Every Smile” – LLS Kicks Off National PR Campaign to Support #1 Partner Burlington
Pluripotent Stem Cell-derived CAR-T and CAR-NK Cells for Immunotherapy of Leukemia and Lymphoma
Cytotoxic cells of the immune system, including T and NK cells, can be targeted to seek out and destroy leukemia, lymphoma and myeloma cells by engineering them to express chimeric antigen receptors (CARs) which empower the cell to home to and kill the cancer cells. Typically, such CAR-T and CAR-NK cells are generated from a patient's own blood, but sometimes heavy pre-treatment with chemotherapy leaves inadequate supplies of T and NK cells.Carmustine
Carmustine is FDA approved to treat people who have myeloma (in combination with prednisone); relapsed or refractory Hodgkin lymphoma (as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy or who fail to respond to primary therapy); relapsed or refractory non-Hodgkin lymphoma (as secondary therapy in combination with other approved drugs).
An integrated liquid biopsy framework for surveillance of residual disease and host immune status of T-cell lymphomas
I aim to develop an accurate disease monitoring system and identify immunologic determinants of development and progression in T-cell lymphoma (TCL). I will integrate noninvasive liquid biopsy methods by high-throughput sequencing. I will study blood samples at various milestones, including pre-diagnostic, diagnostic/baseline, and post-treatment specimens during the natural history of TCL. Using these novel tools and unique specimens, my goal is the development of effective therapies for TCL.Companies Take on Blood Cancer
Corporations usually have enough on their plate, just taking care of business, but at least one has found a creative way to also help generate millions of dollars to fund blood cancer research, education and patient services.
A First-in-human Clinical Trial of CD5 knocked-out Chimeric Antigen T Cells for T-cell Lymphomas
This proposal seeks to develop for the first time in humans a novel CD5 knocked out (KO) anti-CD5 chimeric antigen receptor T cell (CART) product for patients with relapsed or refractory T-cell lymphomas. In Aim#1, we will generate and test a clinical-grade CD5 KO CART5 product, and in Aim#2, we will perform a phase I clinical trial. This project is highly relevant to those parts of the LLS's mission that pertain to the development of personalized and novel therapies for cancer treatment.High Hopes: How a Rising Star Basketball Player’s Story is Bringing Light to the Darkness of Cancer
Each year, from September to November, thousands of illuminated lanterns light up the sky across the country as part of The Leukemia & Lymphoma Society’s Light The Night fundraising campaign – all to end cancer. For one rising star basketball player and Light The Night Honored Hero, Maurice Smith, taking steps to end cancer gave him, and so many others, high hopes for a brighter future.
The Financial Burden of Blood Cancer Treatment for Working-Aged Adults is Growing
Cancer is one of the most expensive medical conditions to treat in the U.S. As a result, patients, survivors, and caregivers—already challenged by the physical and emotional burdens of cancer—often face growing medical debt.
A New Meaning to Mother's Day
By Sarah
A phase 1/2 study of IMT-009, an antibody targeting CD161, in patients with advanced solid tumors or lymphomas
In August 2021, LLS made an equity investment in Immunitas Therapeutics to support the "Phase 1 Clinical Development of IMT-009, an Antibody Targeting CD161, in Patients With Advanced Solid Tumors or Lymphomas."
FDA Approves First CAR T-Immunotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia
The U.S. Food and Drug Administration (FDA) recently announced approval of brexucabtagene autoleucel (Tecartus®) as the first and only CAR T-cell treatment for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). Roughly half of all ALL cases occur in adults, and unlike pediatric ALL, adults have historically had a poor prognosis. This approval, which follows an FDA Breakthrough Therapy Designation and priority review, is a meaningful advance for these patients.
Progress and Challenges in Treating the Blood Cancers: #ASH19
It’s that time of year again, when more than 30,000 scientists specializing in blood cancers and other blood disorders, oncologists and hematologists, pharmaceutical and biotechnology company representatives, and cancer patient advocacy organizations gather in one place to learn about the latest progress in treatments and share new ideas.
This year, we’re in sunny Orlando for the 61st ASH (American Society of Hematology) Annual meeting and Exposition.
Racing Together to Find Blood Cancer Cures
The Leukemia & Lymphoma Society (LLS) Orange County Inland Empire Chapter is excited to announce a new partnership with Auto Club Speedway in Fontana, California. Auto Club Speedway, California’s premier motorsports facility, is geared up to support LLS by hosting a series of fundraising events throughout the coming year.
Auto Club Speedway continues to be involved in making a difference in the local community, and the driving force behind their partnership with LLS is the close connection blood cancer has had on the Speedway family.
